Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

ImmunoGen Inc

IMGN
Current price
29.22 USD +0.12 USD (+0.41%)
Last closed 29.32 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 7 847 849 984 USD
Yield for 12 month +438.12 %
Week
Month
Year
IMGN
21.11.2021 - 28.11.2021

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Address: 830 Winter Street, Waltham, MA, United States, 02451-1477

Analytics

WallStreet Target Price

28.31 USD

P/E ratio

Dividend Yield

1.13 %

Current Year

+108 782 000 USD

Last Year

+69 856 000 USD

Current Quarter

+113 425 000 USD

Last Quarter

+83 153 000 USD

Current Year

+108 606 000 USD

Last Year

+69 856 000 USD

Current Quarter

+111 270 000 USD

Last Quarter

+82 244 000 USD

Key Figures IMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -78 459 000 USD
Operating Margin TTM 22.88 %
PE Ratio
Return On Assets TTM -8.49 %
PEG Ratio
Return On Equity TTM -19.88 %
Wall Street Target Price 28.31 USD
Revenue TTM 287 614 016 USD
Book Value 2.11 USD
Revenue Per Share TTM 1.1 USD
Dividend Share
Quarterly Revenue Growth YOY 637.7 %
Dividend Yield 1.13 %
Gross Profit TTM -104 764 000 USD
Earnings Share -0.28 USD
Diluted Eps TTM -0.28 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY 407.8 %
Profit Margin -25.56 %

Dividend Analytics IMGN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 1.13 %
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation IMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 147.0588
Enterprise Value Revenue 25.4739
Price Sales TTM 27.286
Enterprise Value EBITDA -120.0049
Price Book MRQ 13.9742

Financials IMGN

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators IMGN

For 52 weeks

3.61 USD 29.44 USD
50 Day MA 15.69 USD
Shares Short Prior Month 25 030 174
200 Day MA 12.98 USD
Short Ratio 4.82
Shares Short 32 663 924
Short Percent 12.31 %